Atlas
Back to RCM
Strategic Advisor·RCM

Rob DeMichiei

Board Director and Strategic Advisor (Waystar board director; Health Catalyst strategic advisor; former EVP & CFO of UPMC) at Waystar / Health Catalyst (advisory)

Pittsburgh, Pennsylvania, USA

RD
LinkedIn
Why they matter

Rare buyer-turned-vendor perspective on healthcare RCM: 16 years buying revenue-cycle capability as UPMC's CFO, now governing Waystar's board and advising Health Catalyst on cost analytics.

Background

Rob DeMichiei is the retired Executive Vice President and CFO of UPMC, where he spent 16 years (2004-2020) leading finance, supply chain, and revenue cycle for the $20B+ nonprofit provider-insurer. He previously held executive finance roles at General Electric and spent a decade with Price Waterhouse in Pittsburgh. He now sits on the boards of Waystar, Ampco-Pittsburgh, Ardent Health, and Auto Club Enterprises/AAA, and advises Health Catalyst and Omega Healthcare Management Services.

Notable deals

  • 2025
    Appointed to the board of directors of Ardent Health (NYSE: ARDT), serving on the Audit & Compliance and Nominating & Corporate Governance committees
  • 2020
    Board director of Waystar (Nasdaq: WAY) since 2020, chairing the Audit, Compliance and ESG Committee of the healthcare payments platform
  • 2020
    Joined Health Catalyst (Nasdaq: HCAT) as strategic advisor on cost transformation and financial analytics after retiring as UPMC CFO
  • 2018
    As UPMC EVP & CFO, led finance for the $17B+ integrated system of 30+ hospitals; received Pitt-Johnstown's Distinguished Alumni Award

Call-prep brief

Background

  • Retired EVP & CFO of UPMC (2004-2020), the $20B+ Pittsburgh-based provider-insurer; owned finance, supply chain, and revenue cycle. Earlier career at GE and Price Waterhouse; CPA, Pitt-Johnstown economics grad.
  • Known as a champion of activity-based costing and service-line cost analytics in health systems.

Current focus

  • Waystar board director since 2020; chairs the Audit, Compliance and ESG Committee — deep visibility into RCM vendor economics post-IPO.
  • Strategic advisor to Health Catalyst (cost transformation) and Omega Healthcare Management Services; boards of Ardent Health (April 2025), Ampco-Pittsburgh, and AAA East Central. Civic roles include United Way of Southwestern PA board chair.

What they care about

  • Whether RCM and analytics tools produce measurable margin improvement for health-system CFOs, not dashboards; payer-provider friction; cost accounting as a management discipline.

Recent moves

  • Ardent Health board appointment (April 2025) puts him inside a for-profit hospital operator again — fresh buyer-side signal.

Potential sensitivities

  • As a sitting Waystar director and audit chair, he cannot discuss Waystar non-public information or anything that conflicts with his fiduciary duties; keep questions industry-level. Advisory relationships (Health Catalyst, Omega) are paid; expect measured comments on competitors.

Questions to ask

  1. Which RCM capabilities would he, as a health-system CFO, still pay a premium for today, and which are being commoditized by AI?
  2. Where does vendor consolidation in RCM/clearinghouse infrastructure go over the next five years?
  3. How do health-system CFOs actually evaluate build-vs-buy for cost analytics, and what kills renewals?

Outreach draft

Subject
Former health-system CFO view on RCM
Dear Rob, I'm on the healthcare team at a private equity firm developing a thesis on revenue cycle management platforms serving health systems. Your vantage point is unusual: sixteen years as UPMC's CFO buying and building these capabilities, and now board and advisory roles on the vendor side with Waystar and Health Catalyst. We'd value 30 minutes on where RCM value is genuinely created — automation, payer-provider data exchange, or cost analytics — and which capabilities health-system CFOs will still pay a premium for. Industry-level perspectives only; nothing touching your board obligations. Happy to work around your schedule. Best regards, [Your Name]

Linked companies

Sources